BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18464523)

  • 1. [Collaboration between academia and companies].
    Ueda M
    Nihon Rinsho; 2008 May; 66(5):997-1002. PubMed ID: 18464523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Social effects in regenerative medicine].
    Miyake J
    Nihon Rinsho; 2008 May; 66(5):1004-12. PubMed ID: 18464524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue engineering/regenerative medicine ventures should invest early in market research to understand the future market's needs.
    Gemmiti C
    Tissue Eng Part B Rev; 2013 Apr; 19(2):97-8. PubMed ID: 23327734
    [No Abstract]   [Full Text] [Related]  

  • 4. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical issues for effective collaboration between academia and industry in the field of regenerative medicine in Japan.
    Tsubouchi M; Morishita R; Tabata Y; Matsui S; Kawakami K
    Regen Med; 2008 Jul; 3(4):497-504. PubMed ID: 18588472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlling costs: opportunities for physician-hospital collaborations and ventures.
    Thompson RC; Bishop JR
    Spine (Phila Pa 1976); 2007 May; 32(11 Suppl):S27-32. PubMed ID: 17495583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regenerative medicine 2.0.
    Mason C
    Regen Med; 2007 Jan; 2(1):11-8. PubMed ID: 17465770
    [No Abstract]   [Full Text] [Related]  

  • 8. Future of regenerative medicine: challenges and hurdles.
    Shastri VP
    Artif Organs; 2006 Oct; 30(10):828-34. PubMed ID: 17026584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global strategic partnerships in regenerative medicine.
    French A; Suh JY; Suh CY; Rubin L; Barker R; Bure K; Reeve B; Brindley DA
    Trends Biotechnol; 2014 Sep; 32(9):436-40. PubMed ID: 25150363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dangers in adopting a tissue-engineering-centric agenda: a president's perspective.
    Gilbert JL
    J Biomed Mater Res A; 2011 Feb; 96(2):273-4. PubMed ID: 21171146
    [No Abstract]   [Full Text] [Related]  

  • 11. The Netherlands advancing to the forefront of regenerative medicine.
    Gielen K
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():29-31. PubMed ID: 25457958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint ventures. Hospitals seek creative solutions to grapple with the unbending costs of orthopedic implants.
    Becker C
    Mod Healthc; 2005 Jul; 35(30):24, 26, 28-31. PubMed ID: 16101252
    [No Abstract]   [Full Text] [Related]  

  • 13. Joint-venture proposals strengthen hospital-physician relationship.
    Rovinsky M
    Healthc Financ Manage; 2000 Dec; 54(12):62-5. PubMed ID: 11141690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reimbursement and adoption of advanced therapies: the 5-C framework.
    Malik NN
    Regen Med; 2014; 9(5):573-8. PubMed ID: 25372076
    [No Abstract]   [Full Text] [Related]  

  • 15. Hurdles in tissue engineering/regenerative medicine product commercialization: a survey of North American academia and industry.
    Johnson PC; Bertram TA; Tawil B; Hellman KB
    Tissue Eng Part A; 2011 Jan; 17(1-2):5-15. PubMed ID: 20726816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital/physician relations: collaboration or competition?
    Wolf EJ
    Healthc Exec; 2003; 18(2):18-23. PubMed ID: 12655881
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cell culture, tissue engineering and regenerative medicine. Part I].
    Olszewska-SÅ‚onina DM; Drewa TA
    Wiad Lek; 2006; 59(7-8):585-9. PubMed ID: 17209367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regenerative medicine: the emergence of an industry.
    Nerem RM
    J R Soc Interface; 2010 Dec; 7 Suppl 6(Suppl 6):S771-5. PubMed ID: 20843840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Overview of the Tissue Engineering Market in the United States from 2011 to 2018.
    Kim YS; Smoak MM; Melchiorri AJ; Mikos AG
    Tissue Eng Part A; 2019 Jan; 25(1-2):1-8. PubMed ID: 30027831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Update on tissue engineering: propagation of regenerative medicine for bone and cartilage].
    Takato T
    Clin Calcium; 2008 Dec; 18(12):1683. PubMed ID: 19165974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.